Amegh Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 11-12-2024
- Paid Up Capital ₹ 5.00 M
as on 11-12-2024
- Company Age 17 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 12.00 Cr
as on 11-12-2024
- Satisfied Charges ₹ 3.10 Cr
as on 11-12-2024
- Revenue -8.11%
(FY 2023)
- Profit -4.20%
(FY 2023)
- Ebitda 25.46%
(FY 2023)
- Net Worth 11.52%
(FY 2023)
- Total Assets 33.71%
(FY 2023)
About Amegh Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹12.00 Cr. The company has closed loans amounting to ₹3.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Payal Mohan and Vipul Mohan serve as directors at the Company.
- CIN/LLPIN
U24239MH2007PTC172642
- Company No.
172642
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jul 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Amegh Pharma Private Limited offer?
Amegh Pharma Private Limited offers a wide range of products and services, including Skin Ointment, Pharmaceutical Capsules, Softgel Capsules, Pharmaceutical Tablets, Gelatin Capsules, Soft Gelatin Capsules, Fitness Supplements, Coenzyme Q10 Tablets and Capsules.
Who are the key members and board of directors at Amegh Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Payal Mohan  | Director | 27-Jul-2007 | Current |
| Vipul Mohan | Director | 27-Jul-2007 | Current |
Financial Performance of Amegh Pharma.
Amegh Pharma Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 8.11% decrease. The company also saw a slight decrease in profitability, with a 4.2% decrease in profit. The company's net worth Soared by an impressive increase of 11.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Amegh Pharma?
In 2023, Amegh Pharma had a promoter holding of 100.00%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Sep 2021 | ₹6.00 Cr | Open |
Others Creation Date: 28 Jan 2020 | ₹1.50 Cr | Open |
Others Creation Date: 28 Jan 2020 | ₹1.50 Cr | Open |
How Many Employees Work at Amegh Pharma?
Unlock and access historical data on people associated with Amegh Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Amegh Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Amegh Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
